Regeneron Pharmaceuticals Quarterly Balance Sheet
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regeneron Pharmaceuticals financial position
As of Jun 30, 2026, Regeneron Pharmaceuticals reported total assets of $41.73 billion, up 9.2% from a year earlier against total liabilities of $10.02 billion. Shareholders' equity stood at $31.71 billion, or 76.0% of assets. The company held $2.46 billion in cash and equivalents against $1.99 billion of debt, a net cash position of $469.2 million.
The current ratio (current assets divided by current liabilities) was 3.34, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.06.
Summary generated from market data by MetaCap's automated system. Methodology
Regeneron Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.46B | 2.96B | 3.12B | 2.51B | 2.00B | 3.09B | 2.49B | 2.01B | 1.92B | 2.60B | 2.73B | 2.15B |
| Short-Term Investments | 5.54B | 5.79B | 5.49B | 5.94B | 5.47B | 5.26B | 6.52B | 7.78B | 7.89B | 7.92B | 8.11B | 7.76B |
| Receivables | 6.57B | 5.73B | 5.74B | 5.69B | 5.61B | 5.56B | 6.21B | 6.11B | 5.72B | 5.22B | 5.67B | 5.58B |
| Inventory | 3.08B | 3.10B | 3.20B | 3.25B | 3.21B | 3.19B | 3.09B | 3.02B | 2.87B | 2.71B | 2.58B | 2.56B |
| Total Current Assets | 18.45B | 18.21B | 18.02B | 17.98B | 16.86B | 17.57B | 18.66B | 19.33B | 19.08B | 18.87B | 19.48B | 18.63B |
| Property, Plant & Equipment | 5.46B | 5.27B | 5.12B | 5.00B | 4.84B | 4.69B | 4.60B | 4.44B | 4.31B | 4.23B | 4.15B | 4.01B |
| Intangible Assets | 1.31B | 1.29B | 1.26B | 1.38B | 1.35B | 1.17B | 1.15B | 1.12B | 1.10B | 1.06B | 1.04B | 1.02B |
| Long-Term Investments | 9.83B | 9.79B | 10.26B | 10.29B | 10.06B | 9.28B | 8.90B | 8.49B | 7.72B | 6.98B | 5.40B | 5.78B |
| Total Assets | 41.73B | 40.87B | 40.56B | 40.17B | 38.22B | 37.55B | 37.76B | 37.44B | 36.09B | 34.37B | 33.08B | 32.16B |
| Accounts Payable | 1.16B | 1.03B | 939.00M | 903.80M | 723.90M | 705.50M | 789.50M | 497.30M | 561.70M | 671.30M | 606.60M | 536.60M |
| Total Current Liabilities | 5.53B | 5.11B | 4.37B | 4.43B | 3.67B | 3.57B | 3.94B | 3.66B | 3.51B | 3.58B | 3.42B | 3.60B |
| Long-Term Debt | 1.99B | 1.99B | 1.99B | 1.99B | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Total Liabilities | 10.02B | 9.45B | 9.30B | 9.21B | 8.28B | 8.16B | 8.41B | 8.12B | 7.88B | 7.38B | 7.11B | 7.26B |
| Shareholders' Equity | 31.71B | 31.42B | 31.26B | 30.96B | 29.94B | 29.39B | 29.35B | 29.33B | 28.21B | 26.99B | 25.97B | 24.90B |
| Retained Earnings | 37.62B | 36.42B | 35.80B | 35.05B | 33.68B | 32.38B | 31.67B | 30.76B | 29.41B | 27.98B | 27.26B | 26.10B |
| Total Debt | 1.99B | 1.99B | 1.99B | 1.99B | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Net Cash (Debt) | 6.01B | 6.77B | 6.62B | 6.46B | 5.48B | 6.36B | 7.03B | 7.81B | 7.83B | 8.54B | 8.86B | 7.93B |
This table shows 12 quarterly periods of Regeneron Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow REGN's reporting calendar. What is a balance sheet?